or Try an Advanced Search...

    Technical Analysis for VOR - Vor Biopharma Inc.

    Grade Last Price % Change Price Change
    F 1.85 5.11% 0.09
    VOR closed up 5.11 percent on Wednesday, May 8, 2024, on 1.83 times normal volume.
    Earnings due: May 9
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical VOR trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    Pocket Pivot Bullish Swing Setup 5.11%
    Bollinger Band Squeeze Range Contraction 5.11%
    BB Squeeze Started Range Contraction 5.11%
    20 DMA Resistance Bearish 5.71%
    20 DMA Resistance Bearish 2.78%
    Wide Bands Range Expansion 2.78%
    Gapped Up Strength 2.78%
    Older End-of-Day Signals for VOR ...

       Recent Intraday Alerts

    Alert Time
    Up 5% about 11 hours ago
    20 DMA Resistance about 13 hours ago
    Up 3% about 13 hours ago
    Rose Above 20 DMA about 14 hours ago
    10 DMA Support about 14 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    VOR Chart by TradingView
    Basic chart:

    Profile

    Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Acute Myeloid Leukemia Tyrosine Kinase Receptors Therapies For Cancer Proteins Haematopoiesis Lintuzumab

    Is VOR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 3 Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    May 2 Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
    Apr 4 Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
    Mar 29 Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
    Mar 20 Vor Biopharma GAAP EPS of -$0.39 beats by $0.11
    Mar 20 Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
    Mar 4 Vor Bio to Participate in Upcoming Investor Conferences
    Feb 17 Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company
    Feb 15 2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
    Feb 7 Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    See more VOR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.68
    52 Week Low 1.62
    Average Volume 306,561
    200-Day Moving Average 2.21
    50-Day Moving Average 1.97
    20-Day Moving Average 1.78
    10-Day Moving Average 1.75
    Average True Range 0.12
    RSI (14) 50.50
    ADX 10.73
    +DI 22.20
    -DI 20.68
    Chandelier Exit (Long, 3 ATRs) 1.83
    Chandelier Exit (Short, 3 ATRs) 2.02
    Upper Bollinger Bands 1.95
    Lower Bollinger Band 1.61
    Percent B (%b) 0.71
    BandWidth 19.13
    MACD Line -0.06
    MACD Signal Line -0.07
    MACD Histogram 0.0175
    Fundamentals Value
    Market Cap 125.44 Million
    Num Shares 67.8 Million
    EPS -1.89
    Price-to-Earnings (P/E) Ratio -0.98
    Price-to-Sales 0.00
    Price-to-Book 0.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.09
    Resistance 3 (R3) 2.06 1.96 2.05
    Resistance 2 (R2) 1.96 1.90 1.97 2.04
    Resistance 1 (R1) 1.90 1.86 1.93 1.93 2.02
    Pivot Point 1.80 1.80 1.81 1.81 1.80
    Support 1 (S1) 1.74 1.74 1.77 1.77 1.68
    Support 2 (S2) 1.64 1.70 1.65 1.66
    Support 3 (S3) 1.58 1.64 1.65
    Support 4 (S4) 1.61